One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence
One hundred and ten years after Noon's first clinical report of the subcutaneous application of allergen extracts, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients. It is the only disease-modifying treatment option available and the evidence for its clinical efficacy and safety is broad and undisputed. Throughout recent decades, more insights into the underlying mechanisms, in particular the modulation of innate and adaptive immune responses, have been described. AIT is acknowledged by worldwide regulatory authorities, and following the regulatory guidelines for product development, AIT products are subject to a rigorous evaluation before obtaining market authorization. Knowledge and practice are anchored in international guidelines, such as the recently published series of the European Academy of Allergy and Clinical Immunology (EAACI). Innovative approaches continue to be further developed with the focus on clinical improvement by, for example, the usage of adjuvants, peptides, recombinants, modification of allergens, new routes of administration, and the concomitant use of biologicals. In addition, real-life data provide complementary and valuable information on the effectiveness and tolerability of this treatment option in the clinical routine. New mobile health technologies and big-data approaches will improve daily treatment convenience, adherence, and efficacy of AIT. However, the current coronavirus disease 2019 (COVID-19) pandemic has also had some implications for the feasibility and practicability of AIT. Taken together, AIT as the only disease-modifying therapy in allergic diseases has been broadly investigated over the past 110 years laying the path for innovations and further improvement.
allergen immunotherapy, allergic rhinitis, evidence, innovations, mechanisms
Pfaar, O
85c41012-6b31-4ab5-bc5a-bc89d094e3c4
Bousquet, J
fda25127-be6f-45cd-a455-883cc90d8e0e
Durham, S R
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Kleine-Tebbe, J
37b07cf7-30c3-4c64-9429-d302e05bd008
Larché, M
93db85ef-0a8c-48c1-8f86-98dd9536a5b7
Roberts, G
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Shamji, M H
d68ff179-5c3e-466e-b3d0-07cb3414e618
Gerth van Wijk, R
64d21a3b-ed5a-46ae-a2d2-35478f0ea484
Pfaar, O
85c41012-6b31-4ab5-bc5a-bc89d094e3c4
Bousquet, J
fda25127-be6f-45cd-a455-883cc90d8e0e
Durham, S R
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Kleine-Tebbe, J
37b07cf7-30c3-4c64-9429-d302e05bd008
Larché, M
93db85ef-0a8c-48c1-8f86-98dd9536a5b7
Roberts, G
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Shamji, M H
d68ff179-5c3e-466e-b3d0-07cb3414e618
Gerth van Wijk, R
64d21a3b-ed5a-46ae-a2d2-35478f0ea484
Pfaar, O, Bousquet, J, Durham, S R, Kleine-Tebbe, J, Larché, M, Roberts, G, Shamji, M H and Gerth van Wijk, R
(2021)
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence.
Allergy.
(doi:10.1111/all.15023).
Abstract
One hundred and ten years after Noon's first clinical report of the subcutaneous application of allergen extracts, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients. It is the only disease-modifying treatment option available and the evidence for its clinical efficacy and safety is broad and undisputed. Throughout recent decades, more insights into the underlying mechanisms, in particular the modulation of innate and adaptive immune responses, have been described. AIT is acknowledged by worldwide regulatory authorities, and following the regulatory guidelines for product development, AIT products are subject to a rigorous evaluation before obtaining market authorization. Knowledge and practice are anchored in international guidelines, such as the recently published series of the European Academy of Allergy and Clinical Immunology (EAACI). Innovative approaches continue to be further developed with the focus on clinical improvement by, for example, the usage of adjuvants, peptides, recombinants, modification of allergens, new routes of administration, and the concomitant use of biologicals. In addition, real-life data provide complementary and valuable information on the effectiveness and tolerability of this treatment option in the clinical routine. New mobile health technologies and big-data approaches will improve daily treatment convenience, adherence, and efficacy of AIT. However, the current coronavirus disease 2019 (COVID-19) pandemic has also had some implications for the feasibility and practicability of AIT. Taken together, AIT as the only disease-modifying therapy in allergic diseases has been broadly investigated over the past 110 years laying the path for innovations and further improvement.
Text
Allergy - 2021 - Pfaar - One hundred and ten years of Allergen Immunotherapy A journey from empiric observation to
- Version of Record
More information
Accepted/In Press date: 24 July 2021
e-pub ahead of print date: 27 September 2021
Keywords:
allergen immunotherapy, allergic rhinitis, evidence, innovations, mechanisms
Identifiers
Local EPrints ID: 453796
URI: http://eprints.soton.ac.uk/id/eprint/453796
ISSN: 0105-4538
PURE UUID: 853472d8-aa60-4c4f-8dde-92b0b884117e
Catalogue record
Date deposited: 24 Jan 2022 17:50
Last modified: 17 Mar 2024 03:02
Export record
Altmetrics
Contributors
Author:
O Pfaar
Author:
J Bousquet
Author:
S R Durham
Author:
J Kleine-Tebbe
Author:
M Larché
Author:
M H Shamji
Author:
R Gerth van Wijk
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics